Kadimastem Ltd
KMSTF
Other OTC3.21
USD
-0.10
- -
ISIN
IL0011284614
Return %
Stock
S&P500
1Y
-64.61
18.99
3Y
-65.15
64.75
5Y
-63.02
71.84
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ronen Twito
- Full Time Employees
- 11
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Pinchas Sapir 7 Ness Ziona Israel 74140
- IPO Date
- Feb 1, 2021
- Website
- kadimastem.com
- Similar Companies
- Business
- Kadimastem Ltd (TASE: KDST; OTC: KMSTF) is a clinical-stage biotechnology company that develops off-the-shelf, allogeneic cell therapies derived from human embryonic stem cells (hESCs) for neurodegenerative and metabolic diseases; its lead product candidates include AstroRx, functional astrocytes in Phase 2a clinical development for amyotrophic lateral sclerosis (ALS) and preclinical studies for other neurodegenerative indications, and IsletRx, functional pancreatic islet cells producing insulin and glucagon for the treatment of insulin-dependent Type 1 diabetes without lifelong immunosuppression. Founded in 2008 and headquartered in Ness Ziona, Israel, the company leverages a proprietary platform for scalable production of differentiated cells under GMP conditions, targeting patients with unmet needs in ALS and diabetes through transplantation of lab-differentiated, mature functional cells. In October 2025, Kadimastem completed a merger with NLS Pharmaceutics Ltd, forming NewcelX Ltd (Nasdaq: NCEL), headquartered in Zurich, Switzerland, with research operations in Ness Ziona; Kadimastem shareholders now hold approximately 85% of the combined entity, which integrates cell therapy expertise with small-molecule neuroscience programs and plans to advance AstroRx Phase 2a trials and IsletRx Phase 1 studies. Recent developments include a strategic collaboration with TargetGene announced in October 2025 to develop next-generation gene-edited cell therapies under NewcelX, up to $28 million in equity financing in March 2025 to support the merger and clinical programs, and continued BIRD Foundation support for the ITOL-102 diabetes program post-merger. NewcelX operates globally with a focus on regenerative medicine, led by Executive Chairman and CEO Ronen Twito and Chief Scientific Officer Prof. Michel Revel.
NewcelX Provides Business and Strategic Roadmap Update Following Closing of Merger with NLS Pharmaceutics Ltd.